医药行业创新药周报:MNC2025年一季报梳理

华创证券有限责...
Yesterday

辉瑞公布2025Q1财报,实现总营收137.15亿美元(-8%),主要归因于新冠抗病毒药物Paxlovid的全球销售额下降15亿美元(-75%)。辉瑞维持2025年全年财务指引不变,预计收入在610-640亿美元。辉瑞还将通过新增削减计划节省12亿美元开支。自2023年10月首次公布成本调整计划以来,辉瑞已多次更新削减成本计划,目前,削减成本总目标达77亿美元。销售方面,治疗转甲状腺素蛋白淀粉样变...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10